TY - CHAP
T1 - Radioprotectors, Radiomitigators, and Radiosensitizers
AU - Montoro, Alegría
AU - Obrador, Elena
AU - Mistry, Dhruti
AU - Forte, Giusi I.
AU - Bravatà, Valentina
AU - Minafra, Luigi
AU - Calvaruso, Marco
AU - Cammarata, Francesco P.
AU - Falk, Martin
AU - Schettino, Giuseppe
AU - Ahire, Vidhula
AU - Daems, Noami
AU - Boterberg, Tom
AU - Dainiak, Nicholas
AU - Chaudhary, Pankaj
AU - Baatout, Sarah
AU - Mishra, Kaushala Prasad
N1 - Score=10
Publisher Copyright:
© The Editor(s) (if applicable) and The Author(s) 2023.
PY - 2023/1/1
Y1 - 2023/1/1
N2 - This chapter gives an overview of molecules and mechanisms able to intervene with the biological effects of ionizing radiation (IR), either related to their clinical use in radiotherapy or in the field of radiation protection in case of an accidental exposure to radiation and/or nuclear emergencies. According to the National Cancer Institute, “radiomodifiers” can be classified into (a) radioprotectors (protect molecules and tissues from direct and indirect damage induced by IR) or (b) radiomitigators (reduce and help to repair damage), depending on whether they are administered pre-or post-IR exposure, respectively. Most of them are free radical scavengers and antioxidants (or enhancers of the antioxidant defenses), increase DNA repair mechanisms, have anti-inflammatory properties, and/or prevent cell death. On the other hand, (c) radiosensitizers directly or indirectly enhance DNA damage and ROS production, increasing IR toxicity on tumor cells, thus they are used to increase radiotherapy efficacy in cancer patients. The section “Radionuclides and methods to treat contaminated individuals” describes the medical consequences and treatment modalities of internal contamination by radionuclides. Overall, the chapter discusses the effects of most currently known radiomodifiers, their specific properties, and their mechanisms of action, by emphasizing results obtained in recent preclinical and clinical trials.
AB - This chapter gives an overview of molecules and mechanisms able to intervene with the biological effects of ionizing radiation (IR), either related to their clinical use in radiotherapy or in the field of radiation protection in case of an accidental exposure to radiation and/or nuclear emergencies. According to the National Cancer Institute, “radiomodifiers” can be classified into (a) radioprotectors (protect molecules and tissues from direct and indirect damage induced by IR) or (b) radiomitigators (reduce and help to repair damage), depending on whether they are administered pre-or post-IR exposure, respectively. Most of them are free radical scavengers and antioxidants (or enhancers of the antioxidant defenses), increase DNA repair mechanisms, have anti-inflammatory properties, and/or prevent cell death. On the other hand, (c) radiosensitizers directly or indirectly enhance DNA damage and ROS production, increasing IR toxicity on tumor cells, thus they are used to increase radiotherapy efficacy in cancer patients. The section “Radionuclides and methods to treat contaminated individuals” describes the medical consequences and treatment modalities of internal contamination by radionuclides. Overall, the chapter discusses the effects of most currently known radiomodifiers, their specific properties, and their mechanisms of action, by emphasizing results obtained in recent preclinical and clinical trials.
KW - Antioxidants
KW - Contamination
KW - Decorporation
KW - Radiomitigator
KW - Radionuclide
KW - Radioprotector
KW - Radiosensitizer
KW - Radiotherapy
UR - http://www.scopus.com/inward/record.url?scp=85181141935&partnerID=8YFLogxK
U2 - 10.1007/978-3-031-18810-7_11
DO - 10.1007/978-3-031-18810-7_11
M3 - Chapter
AN - SCOPUS:85181141935
SN - 9783031188091
SP - 571
EP - 628
BT - Radiobiology Textbook
PB - Springer International Publishing
ER -